Financial Daily from THE HINDU group of publications
Saturday, Jul 16, 2005
Financial Daily from THE HINDU group of publications Saturday, Jul 16, 2005 |
|
|
|
|
|
Corporate
-
Announcements Nicholas Piramal's cancer drug enters phase-I/II trials Our Bureau
Mumbai , July 15 DRUG major Nicholas Piramal India Ltd has said that its prospective anti-cancer drug molecule has entered into Phase I and II clinical studies. "After obtaining the necessary permissions from the Canadian regulatory authorities, a patient was recently infused intravenously with P276-00 at an Oncology centre in Canada," a note from the company said. Further, it added that it could take 9-12 months to enrol 30-35 patients to complete the Phase I/II study that will help determine a safe and possible efficacious dose, which will be used for further clinical studies. The prospective cancer drug molecule is the first in a series of compounds from the company's research centre to enter into clinical trials. It is an inhibitor of a key protein that is required by the cells to divide. Based on the initial laboratory data, P276-00 appears suitable as an agent to treat lung, breast and colon cancers, the note said.
Article E-Mail :: Comment :: Syndication :: Printer Friendly Page
|
Stories in this Section |
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | Business Line | The Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |
Copyright © 2005, The
Hindu Business Line. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of
The Hindu Business Line
|